drugset / Trial / NCT04871204

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

NCT04871204

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to clarify whether octreotide therapy can reduce undesired postoperative weight loss, increase health-related quality of life and improve the appetite after surgery for esophageal or gastric cancer.

Timeline

Start
2021-06-16
Primary completion
2024-02-21
Completion
2024-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 10 mg Intramuscular